Morgan Stanley maintains price target on Engene Holdings shares By Investing.com

Morgan Stanley reaffirmed its Overweight rating and a $40.00 price target for shares of Engene Holdings Inc. (NASDAQ: ENGN), following the release of initial data on detalimogene, a new therapy for non-muscle invasive bladder cancer (NMIBC). The firm acknowledged the early stage of the data but recognized the therapy’s potential significance in the NMIBC treatment landscape.

The initial data from Engene’s detalimogene LEGEND study was met with mixed reactions, as some investors compared it unfavorably to competing treatments cretostimogene and TAR-200. Despite these comparisons, Morgan Stanley expressed optimism about detalimogene’s future, citing its potential to become an important therapy for NMIBC.

The preliminary results included data from 21 out of the 100 targeted patients in the study. Morgan Stanley emphasized the need for caution in drawing conclusions at this stage due to the limited data set and the fact that the study’s outcomes could evolve as more patients are enrolled. The protocol amendment to reinduce Ta patients is also expected to influence future findings.

The firm noted that while the early results are promising, the lack of near-term clinical catalysts is likely to keep investor attention at bay until the next significant update, which is anticipated in 2025. This timeline suggests that it may be some time before the full impact of detalimogene on the NMIBC market can be assessed.

In summary, Morgan Stanley’s position on Engene Holdings remains positive, with expectations for detalimogene to potentially shape the NMIBC treatment paradigm. The firm’s price target and rating stand firm despite the current uncertainties and the long wait for further updates on the therapy’s efficacy and market potential.

In other recent news, Engene Holdings Inc. announced key developments concerning their gene therapy, EG-70, which is currently in clinical trials for treating non-muscle invasive bladder cancer (NMIBC). The firm Oppenheimer maintained its Outperform rating for Engene, projecting the potential of EG-70 due to its non-viral gene therapy nature and convenience of use. The firm also anticipates preliminary reveal of EG-70’s registrational cohort results, which are significant for validating the therapy’s efficacy.

Engene’s robust financial position was also highlighted, following a $200 million private investment in public equity. The company’s sales are projected to reach approximately $530 million by 2031, following an expected U.S. approval and product launch in 2027.

Leadership changes were also announced, with the appointment of Ron Cooper as the new Chief Executive Officer and the promotion of Dr. Raj Pruthi to Chief Medical Officer. The company also expanded its Board of Directors with the addition of Paul Hastings and Wouter Joustra. Engene is preparing to submit a Biologics License Application in early 2026, with interim data from a pivotal Phase 2 study expected to be announced in mid-2024.

InvestingPro Insights

Engene Holdings Inc. (NASDAQ: ENGN) presents a curious case for investors, with a market capitalization of $283.42 million underscoring its position as a smaller player in the biotech field. According to InvestingPro data, the company’s P/E ratio stands at -1.58, reflecting the market’s anticipation of future profits despite current losses. The adjusted P/E ratio for the last twelve months as of Q3 2024 even further accentuates this point, sitting at -3.7. This indicates that investors are pricing Engene’s shares with the expectation of growth, albeit acknowledging its current unprofitability.

InvestingPro Tips suggest that the negative PEG ratio of -0.05 could imply that the market expects Engene’s situation to improve significantly in the future. Despite the company’s operating income showing a sizable loss of $55.28 million in the same period, the InvestingPro Fair Value estimate is $7.33, which is higher than the previous close price of $6.25. This suggests that there may be some upside potential for the stock, aligning with Morgan Stanley’s optimistic view on the company’s long-term prospects.

With 21 additional tips available on InvestingPro, investors can delve deeper into the company’s financial health and potential. As the next significant update on detalimogene is not expected until 2025, these insights could prove valuable for those considering an investment in Engene Holdings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.